The difference between Obinutuzumab and Rituximab

Obinutuzumab and rituximab are both monoclonal antibody drugs used to treat hematological malignancies, but they differ in some aspects. Their structures are different. Otuzumab is a humanized IgG1κ monoclonal antibody, while rituximab is a humanized IgG1κ monoclonal antibody.

They have different affinities forCD20 antigen. Otuzumab has a higher affinity and can bind to and eliminate CD20-positive B cells more effectively. In contrast, rituximab has lower affinity. Additionally, their routes of use and dosages vary. Otuzumab is usually administered IV (intravenous injection), while rituximab can be administered IV or SC (subcutaneous injection). In addition, the therapeutic dose of otuzumab is relatively high and requires pretreatment to reduce the occurrence of allergic reactions; while the dose of rituximab is lower and pretreatment is generally not required. Their use in clinical research also varies. Otuzumab is mainly used to treat chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), while rituximab is not only used in these diseases, but is also widely used in the treatment of other B-cell malignancies, such as diffuse large B-cell lymphoma (DLBCL) and autoimmune diseases such as rheumatoid arthritis.

The original drug of Otuzumab has been launched in China and has entered the scope of medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of 1000mg (40ml)*1 bottle may be around 9,000 yuan, which is a strictly controlled drug. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.